2nd Quarter - Report
MEHLMAN CONSULTING, INC. for FOREST LABORATORIES INC
Client
Income
$60,000
Expenses
—
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Health reform and related health care issues, including potential changes to Medicaid rebate.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KELLY RUCKER BINGEL | — |
| JAMIE BROWN | — |
| DAVID CASTAGNETTI | — |
| COLETTE DESMARAIS | — |
| ELISE FINLEY PICKERING | — |
| JONATHAN RUSSELL HOGANSON | — |
| BRUCE MEHLMAN | — |
| STACEY RAMPY | — |
| DEAN ROSEN | — |
| DAVID R THOMAS | — |
| ALLEN L THOMPSON | — |
| ALEX VOGEL | — |
Health Issues HCR
Health reform and related health care issues, including potential changes to Medicaid rebate. S.525/H.R.1298, The Pharmaceutical Market Access and Drug Safety Act of 2009.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KELLY RUCKER BINGEL | — |
| JAMIE BROWN | — |
| DAVID CASTAGNETTI | — |
| COLETTE DESMARAIS | — |
| ELISE FINLEY PICKERING | — |
| JONATHAN RUSSELL HOGANSON | — |
| BRUCE MEHLMAN | — |
| STACEY RAMPY | — |
| DEAN ROSEN | — |
| DAVID R THOMAS | — |
| ALLEN L THOMPSON | — |
| ALEX VOGEL | — |
Government Issues GOV
Health reform and related health care issues, including potential changes to Medicaid rebate. Tax policy (repatriation). S.525/H.R.1298, The Pharmaceutical Market Access and Drug Safety Act of 2009.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KELLY RUCKER BINGEL | — |
| JAMIE BROWN | — |
| DAVID CASTAGNETTI | — |
| COLETTE DESMARAIS | — |
| ELISE FINLEY PICKERING | — |
| JONATHAN RUSSELL HOGANSON | — |
| BRUCE MEHLMAN | — |
| STACEY RAMPY | — |
| DEAN ROSEN | — |
| DAVID R THOMAS | — |
| ALLEN L THOMPSON | — |
| ALEX VOGEL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.